Crespo-Rodriguez, Eva
Bergerhoff, Katharina
Bozhanova, Galabina
Foo, Shane
Patin, Emmanuel C
Whittock, Harriet
Buus, Richard
Haider, Syed
Muirhead, Gareth
Thway, Khin
Newbold, Kate
Coffin, Robert S
Vile, Richard G
Kim, Dae
McLaughlin, Martin
Melcher, Alan A
Harrington, Kevin J
Pedersen, Malin http://orcid.org/0000-0003-1887-733X
Clinical trials referenced in this document:
Documents that mention this clinical trial
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
https://doi.org/10.1136/jitc-2020-000698
Thyroid cancer
https://doi.org/10.1016/s0140-6736(16)30172-6
Novel therapeutics in low-grade serous ovarian cancer
https://doi.org/10.1136/ijgc-2022-003677
Documents that mention this clinical trial
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
https://doi.org/10.1136/jitc-2020-000698
Documents that mention this clinical trial
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
https://doi.org/10.1136/jitc-2020-000698
Funding for this research was provided by:
Oracle Cancer Trust
Cancer Research UK (C16708/A21855)
Anthony Long Charitable Trust
GetAhead Charitable Trust